Increased serum XXXX during treatment of @entity1378 with antithyroid drugs.

@entity1 @entity66 @entity3937 @entity2743 @entity1356 @entity1378 @entity5012 @entity64137
Serum @entity1356 ( @entity1356 ) and soluble interleukin-2 receptor (sIL-2R) levels were examined in @entity1 with @entity1378 due to @entity66 (TNG) before and during antithyroid drug therapy. A total of 32 @entity1 were studied; 23 @entity1 (14 with @entity2743 and nine with TNG) were in a @entity1378 state (group A) and nine @entity1 (four with @entity2743 and five with TNG) were in a euthyroid state, under @entity5012 or @entity3937 treatment (group B). Ten @entity1378 @entity1 from group A (seven with @entity2743 and three with TNG) were also examined while euthyroid on treatment (Subgroup A). Serum was taken from all @entity1 for the measurement of sIL-2R, @entity1356 , total T4 (TT4), total T3 (TT3) and TSH concentrations. The results were compared with those from 30 normal controls. Serum sIL-2R levels were higher in Group A (671.3 +/- 74.0 U @entity64137 , mean +/- SE), than in Group B (214.1 +/- 61.8 U @entity64137 ) and controls (149 +/- 14.8 U @entity64137 ), P < 0.001. Similarly, the subgroup of 10 @entity1 had higher levels of sIL-2R during the @entity1378 phase than while euthyroid (P < 0.001). There was a positive correlation between sIL-2R values and levels of T4 and T3. In contrast, serum @entity1356 levels were higher in Group B @entity1 (197.5 +/- 39.2 pg @entity64137 ) compared with those in Group A (66.5 +/- 17 pg @entity64137 , P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
